136.70 0.00 (0.00%)
After hours: 5:09PM EDT
|Bid||136.70 x 1300|
|Ask||136.80 x 2900|
|Day's Range||136.70 - 136.80|
|52 Week Range||31.70 - 137.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||95.00|
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.
Last month, the American Cancer Society expanded opportunities for colorectal cancer-testing companies when it called for people with average risk profiles to begin screening at age 45 instead of 50. Inc., which went public in 2005, said clinical trials showed its Oncotype DX test could definitively identify which early-stage breast cancer patients would and wouldn’t benefit from chemotherapy—news that propelled its stock price to all-time highs. Inc., which Third Rock Ventures formed in 2009 and took public in 2013.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.
Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.
Roche Holding AG on Tuesday said it would pay $2.4 billion to buy the shares it doesn’t already own in Foundation Medicine Inc., furthering its bet on personalized cancer care. The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer.
Foundation Medicine rocketed to a record high Tuesday after Swiss drugmaker Roche agreed to buy it in a pharmaceutical merger for $2.4 billion.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.
The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer. The deal to take full control of Foundation comes after Roche first bought a stake in the company in 2015.
ZURICH/LONDON (Reuters) - Swiss drugmaker Roche (:ROG.S) is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) (:FMI.O), raising its bet on the U.S. genomic profiling group's ability to personalize cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.
Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
Foundation Medicine, Inc. today announced that new data generated from its comprehensive genomic profiling assays will be presented at the American Society of Clinical Oncology Annual Meeting from June 1-5, 2018 in Chicago.
Foundation Medicine, Inc. (FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors. The companion diagnostic tests will leverage FoundationOne CDx™, Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) assay for all solid tumors incorporating multiple companion diagnostics. The companies will collaborate on the development of a pan-cancer companion diagnostic to measure MSI.
NEW YORK, NY / ACCESSWIRE / May 22, 2018 / U.S. equities closed up on Monday, with the Dow Jones bouncing back to 25,000 milestones. Tension between U.S. and China eased after statement from Treasury Secretary ...
NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Front ...